About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon Quarterly Results
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
     
 
Financials

Financial Results

 
 
 

Current Financial Year 2018-19

  FY 18-19 Q1 H1 9M FY
  Notice Ad Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release - -
  Press Release Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release Biocon_Q3 FY19_Press Release -
  Fact Sheet Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release Biocon_Q3 FY19_Press Release -
  Transcript of the Call Biocon_Q1FY18_CallTranscript Biocon_Q2FY18_Call_Transcript Biocon_Q3FY19_Call_Transcript -
  Newspaper Advertisement Biocon_Q1 FY18_Press Release Biocon_Q2 FY19_Press Release Biocon_Q3 FY19_Press Release -
  Results Biocon_Q1 FY18_Press Release Biocon_Q2 FY18_Press Release Biocon_Q3 FY19_Press Release -
  Investor Presentation Investor Presentation Investor Presentation Investor Presentation -

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q3FY19

Particulars 

Q3FY19

Q3FY18

Growth

INCOME

Small Molecules

469

369

27%

Biologics

449

190

136%

Branded Formulations

212

156

36%

Research Services

467

388

20%

Inter-segment

-56

-45

26%

Revenue from Operations#

1,541

1,058

46%

Other Income

25

34

-24%

TOTAL REVENUE

1,566

1,092

43%

EBITDA

406

256

59%

PBT

289

150

93%

Net Profit

217

92

136%

Exceptional item (net of tax)

6

-

Net Profit (adjusted for exceptional item)

211

92

130%

R&D Expenses in P&L

77

53

45%

Gross R&D Spends

106

94

12%

EBITDA Margin

26%

23%

Core EBITDA Margin

32%

27%

Net Profit Margin*

14%

8%

#includes Licensing Income

7

12

Year 2017-18 Financial Highlights

In Rs. Crore 
  FY 17-18 Q1 H1 9M FY
  Revenue 988 1019 1092 1237
  EBITDA 246 233 256 300
  Net Profit 81 69 92 130
  R&D Expenses in P&L 58 54 53 51
  Total R&D Spends 96 93 94 98
  EBITDA Margins 25% 23% 23% 24%
  Core EBITDA Margin 29% 27% 27% 26%
  Net Profit Margins 8% 7% 8% 11%
 
  * As per the new accounting standard: Ind-AS  
  FY16-17  FY15-16  FY15-16  FY14-15  FY13-14  FY12-13  FY11-12  FY10-11  FY09-10  FY08-09  FY07-08  FY06-07  FY05-06  FY04-05 

 
Quarterly Results
 FY17-18
 FY16-17
 FY15-16
 FY14-15
 FY13-14
 FY12-13
 FY11-12
 FY10-11
 FY09-10
 FY08-09
 FY07-08
 FY06-07
 FY05-06
 FY04-05
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved